Randomized Trial of Targeted Indoor Spraying to Prevent Aedes-Borne Diseases.

7 major claims checked against the paper's own evidence: all adequately supported.

Recomputed 1 test: 1 consistent, 0 inconsistent, 1 via agent-written checks.

6 copyedit issues flagged: mostly consistency, other, typo.

Checked 32 references: 29 verified — 3 not checked.

3 data/code links checked; 2 live.

The manuscript is not ready for submission in its current form. The absence of a data availability statement (a journal requirement for most clinical trial venues) and the lack of IRB specifics are likely to result in an administrative return. After adding the data availability statement, naming the IRBs with protocol numbers, reporting p-values, verifying model assumptions, and adding a CONSORT checklist, the paper would be ready for submission.

1. 1.
   HIGHdata code

   Add a Data Availability statement specifying where de-identified participant data and study materials will be deposited (e.g., a public repository like Zenodo, Dryad, or a managed-access platform like Vivli), and remove the current text that only describes data management ('maintained in REDCap').

   Without a data availability statement, most clinical trial journals will return the manuscript administratively.
2. 2.
   HIGHethics

   Replace the vague IRB statement with the full name(s) of the specific institutional review board(s) that approved the protocol and include the protocol number(s) in the Methods section (Trial Design and Oversight).

   Named IRBs and protocol numbers are a standard ethics reporting requirement; a generic statement is insufficient for submission.
3. 3.
   HIGHstatistics

   Report exact p-values (e.g., p = 0.XX) alongside all confidence intervals for primary and secondary efficacy analyses in the Results text and Table 1.

   Exact p-values are required for meta-analysis, reader interpretation, and compliance with reporting guidelines; 'not statistically significant' without a p-value is imprecise.
4. 4.
   HIGHstatistics

   Add verification of the proportional hazards assumption for all Cox models used in the primary analysis in the Methods (Statistical Analysis section), and report the result (e.g., Schoenfeld residuals test, or a statement that the assumption was verified).

   Without assumption verification, the validity of the hazard ratio estimates is uncertain, and reviewers will flag this omission.
5. 5.
   HIGHdata code

   Upload the custom analysis code (R scripts) to a public repository (e.g., GitHub, Zenodo) and cite the DOI in the manuscript under a new Code Availability section.

   Code sharing is essential for reproducibility; absence of code is a significant gap that journals increasingly require.
6. 6.
   HIGHreporting

   Add a statement that the manuscript adheres to the CONSORT 2010 statement extension for cluster-randomized trials, and include the completed CONSORT checklist as a supplementary file.

   Reporting guidelines are expected by journals and reviewers for clinical trials; omission is a common reason for revision requests.
7. 7.
   HIGHreporting

   Add a rationale for the unblinded design (e.g., why a sham spraying procedure was not feasible or ethical) in the Methods, Trial Design and Oversight section.

   Unblinded trials are at risk of performance/detection bias; a clear justification is required to allow readers to assess the risk.
8. 8.
   HIGHreporting

   Add a Pre-specified Exclusion Criteria and Outlier Handling subsection in the Methods (Trial Cohort and Randomization) describing which children were excluded from the per-protocol analysis and why, and how outliers (if any) were handled.

   The per-protocol analysis is the primary analysis; the criteria for inclusion in this analysis must be transparent to avoid selection-bias concerns.
9. 9.
   MEDIUMrigor

   Report the weight and race/ethnicity of the cohort in the baseline characteristics table (Results, Trial Cohort).

   Weight and race/ethnicity are standard demographic variables in clinical trials; their absence makes the biological variables reporting incomplete.
10. 10.
    MEDIUMrigor

    Specify the manufacturer and catalog number of the ELISA kits used for serological testing in the Methods or Supplementary Materials.

    Reagent identification allows reproducibility; 'commercially available ELISAs' is too vague.
11. 11.
    MEDIUMreporting

    Add a formal statement that the study complies with the Declaration of Helsinki or other recognized ethical framework in the Methods, Trial Design and Oversight section.

    Regulatory compliance should reference an ethical framework, not just trial registration requirements.
12. 12.
    LOWcopyedit

    Fix the typo 'Aedes -borne' to 'Aedes-borne' in the Abstract (Methods).

    Inconsistent hyphenation is a minor copyedit issue that is easily corrected.
13. 13.
    LOWcopyedit

    Add a colon after 'Trial registration' in the Abstract (e.g., 'Trial registration:') for consistency with other subheadings.

    Consistency in formatting is a minor polish issue.
14. 14.
    LOWcopyedit

    Rephrase 'Two multi-symptom (i.e., nausea, watery eyes, diarrhea and vomiting) adverse event cases...' to 'Two cases of multi-symptom adverse events (nausea, watery eyes, diarrhea, and vomiting)...' in the Abstract (last sentence) for clarity and use of serial comma.

    Awkward phrasing and inconsistent comma style are minor readability issues.